QMSAdvisor

FDA Inspections

FDA Compliance Follow-Up Inspection

After an OAI inspection, a warning letter or other regulatory action, FDA comes back to check. A compliance follow-up inspection tests whether the corrections and corrective actions you committed to were completed, whether they work, and whether the problem reaches further than the original findings.

Request an assessmentRehearse it in the simulator

At a Glance

Conducted by
FDA investigators
Purpose
Verifies corrective actions after prior OAI findings, a warning letter or other regulatory action
Framework
An inspection type under Compliance Program 7382.850
Possible outcome
NAI, VAI or OAI classification; further action if violations persist

What It Is

Compliance Program 7382.850 lists compliance follow-up as its own inspection type. Its job is verification. FDA has already found problems, through an OAI inspection, a warning letter or another regulatory action, and the follow-up checks what you did about them.

The investigator works from the history: the earlier observations, your Form 483 response and any warning letter response. Each commitment gets compared with the evidence. Completed actions need records, ongoing ones need to be where you said they would be, and effectiveness claims need data.

A follow-up can also look beyond the original findings. If the root cause was systemic, investigators may check whether the same weakness affects other products, processes or sites. FDA verifies corrective actions before it issues a close-out letter for a warning letter, and a follow-up inspection is one way it does that.

Who Conducts It

FDA investigators conduct it, with access to the earlier inspection record and your correspondence with the agency. Treat every past commitment as something they can check.

The people who led remediation should be ready to walk through each action, and leadership should be ready to explain the oversight that kept remediation on track.

What Triggers It

  • A prior inspection classified Official Action Indicated (OAI)
  • A warning letter and the corrective actions you committed to in your response
  • Other regulatory actions where FDA needs to confirm that violations were corrected
  • Dated commitments in an inspection response that FDA chooses to verify on site

What They Look At

  • Each Prior Observation

    One by one, the investigator compares the original finding, your response, and the evidence of what you actually did.

  • Corrections Versus Corrective Actions

    Whether you fixed the specific instances cited and also fixed the system that produced them.

  • Effectiveness Verification

    Data showing the corrective action worked over time, not just a completed task in a CAPA record.

  • Systemic Reach

    Whether the same weakness affects other products, lines, procedures or sites, and whether your own review looked for it.

  • Retrospective Reviews

    Where a finding implied past records were wrong (missed MDRs, unvalidated processes, unevaluated complaints), whether you went back and dealt with them.

  • Management Oversight of Remediation

    Whether leadership tracked the remediation, resourced it and stepped in when it slipped.

How to Prepare

  1. 01

    Build a Commitment Register

    List every commitment from your 483 and warning letter responses, with its promised date, current status and the evidence that proves it.

  2. 02

    Audit Your Own Evidence

    Have someone independent of the remediation check each item against its records, the way an investigator would.

  3. 03

    Prove Effectiveness With Data

    Gather trend data, repeat audits or sampling results that show the problem has stopped recurring.

  4. 04

    Explain Every Slipped Date

    Where a commitment moved, document why, who approved the change and what interim controls protected product in the meantime.

  5. 05

    Look for the Same Problem Elsewhere

    Extend your review to other products and processes now, before the investigator does it for you.

Common Pitfalls

  • Responses that promised more than the team could deliver, leaving dated commitments unmet.
  • CAPAs closed when tasks were completed, with no effectiveness check.
  • Fixing the cited examples while the procedure that produced them stays unchanged.
  • Retrospective reviews scoped too narrowly to find the real extent of the problem.
  • Remediation records scattered across email and spreadsheets with no single view of status.

How QMSAdvisor Helps

  • Each prior observation and commitment becomes a finding in the action plan, with an owner, due date and the evidence required to close it.
  • Advisors review submitted evidence and accept it or request a revision, and every resubmission records what changed.
  • CAPA records keep correction, root cause, corrective action and effectiveness verification in one place, with an immutable activity history.
  • An FDA Inspection Simulator session built around the original observations, so remediation leads practice walking an investigator through the evidence.

Standards and Regulations Involved

Questions About the FDA Compliance Follow-Up Inspection

When does FDA conduct a compliance follow-up inspection?

After an OAI inspection, a warning letter or other regulatory action, when FDA needs to verify corrective actions. FDA decides the timing, so keep remediation evidence ready from the day you submit your response.

What does it take to close out a warning letter?

FDA may issue a close-out letter once it has evaluated your corrective actions and is satisfied the violations were addressed, and that verification can include a follow-up inspection. A close-out letter doesn't excuse future violations.

What if we missed some of our committed dates?

Document why each date moved, who approved the change and what interim controls were in place. An explained, controlled delay reads very differently from an unexplained one. Firms commonly send FDA progress updates, which is a good place to note changes to the plan.

Will they only look at the original observations?

Those come first, but investigators can check whether the same weakness exists elsewhere. Prepare as if your corrective actions will be tested for systemic reach, since that's what a strong corrective action should cover.

Related Audits and Inspections

Primary Sources

FDA Inspection Simulator

Practice This Inspection With an Advisor as the Investigator

Timed document requests, a working back room, scored interviews and practice observations at closeout. A rehearsal, never an FDA document.

See how the simulator works

Request an Assessment

Prepare for Your FDA Compliance Follow-Up Inspection With an Advisor

Tell us what's coming and when, and an advisor will scope readiness work around it. Please don't send confidential documents yet: secure upload is set up after onboarding.

Request an assessmentSee the inspection simulator